Skip to main content
Top
Published in: European Spine Journal 1/2006

01-01-2006 | Review

Economic evaluations: a new avenue of outcome assessment in spinal disorders

Authors: Nicole van der Roer, Norbert Boos, Maurits W. van Tulder

Published in: European Spine Journal | Special Issue 1/2006

Login to get access

Abstract

The number of economic evaluations in the field of spinal disorders and methodological studies have increased in the last decade. The objective of this paper is to provide an overview of current views on economic evaluations in the field of spinal disorders and to facilitate clinicians to interpret and use results from these studies. A full economic evaluation compares both costs and effects of two or more interventions. Key elements of economic evaluations such as identifying adequate alternatives, analytical perspective, cost methodology, missing values and sensitivity analyses are addressed. Further emphasis is placed on the interpretation of results of economic evaluations conducted alongside randomised clinical trials. Incremental cost–effectiveness ratios, cost–effectiveness planes, acceptability curves and cost–effectiveness thresholds are discussed. The contents may aid in taking the efficacy ‘hurdle’ in the field of spinal disorders.
Literature
1.
go back to reference (2004) United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: cost effectiveness of physical treatments for back pain in primary care. BMJ 329:1381 (2004) United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: cost effectiveness of physical treatments for back pain in primary care. BMJ 329:1381
2.
go back to reference Barber JA, Thompson SG (1998) Analysis and interpretation of cost data in randomised controlled trials: review of published studies. BMJ 317:1195–1200PubMed Barber JA, Thompson SG (1998) Analysis and interpretation of cost data in randomised controlled trials: review of published studies. BMJ 317:1195–1200PubMed
3.
go back to reference Barber JA, Thompson SG (2000) Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 19:3219–3236PubMedCrossRef Barber JA, Thompson SG (2000) Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 19:3219–3236PubMedCrossRef
4.
go back to reference Birch S, Gafni A (1993) Changing the problem to fit the solution: Johannesson and Weinstein’s (mis) application of economics to real world problems. J Health Econ 12:469–476PubMedCrossRef Birch S, Gafni A (1993) Changing the problem to fit the solution: Johannesson and Weinstein’s (mis) application of economics to real world problems. J Health Econ 12:469–476PubMedCrossRef
5.
go back to reference Bombardier C (2000) Outcome assessments in the evaluation of treatment of spinal disorders: summary and general recommendations. Spine 25:3100–3103PubMedCrossRef Bombardier C (2000) Outcome assessments in the evaluation of treatment of spinal disorders: summary and general recommendations. Spine 25:3100–3103PubMedCrossRef
6.
go back to reference Briggs A, Fenn P (1998) Confidence intervals or surfaces? Uncertainty on the cost–effectiveness plane. Health Econ 7:723–740PubMedCrossRef Briggs A, Fenn P (1998) Confidence intervals or surfaces? Uncertainty on the cost–effectiveness plane. Health Econ 7:723–740PubMedCrossRef
7.
go back to reference Briggs AH, Gray AM (1999) Handling uncertainty in economic evaluations of healthcare interventions. BMJ 319:635–638PubMed Briggs AH, Gray AM (1999) Handling uncertainty in economic evaluations of healthcare interventions. BMJ 319:635–638PubMed
8.
9.
go back to reference Briggs AH, O’Brien BJ, Blackhouse G (2002) Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost–effectiveness studies. Annu Rev Public Health 23:377–401PubMedCrossRef Briggs AH, O’Brien BJ, Blackhouse G (2002) Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost–effectiveness studies. Annu Rev Public Health 23:377–401PubMedCrossRef
10.
go back to reference Briggs A, Clark T, Wolstenholme J, Clarke P (2003) Missing presumed at random: cost-analysis of incomplete data. Health Econ 12:377–392PubMedCrossRef Briggs A, Clark T, Wolstenholme J, Clarke P (2003) Missing presumed at random: cost-analysis of incomplete data. Health Econ 12:377–392PubMedCrossRef
11.
go back to reference Coyle D (1996) Statistical analysis in pharmacoeconomic studies. A review of current issues and standards. Pharmacoeconomics 9:506–516PubMedCrossRef Coyle D (1996) Statistical analysis in pharmacoeconomic studies. A review of current issues and standards. Pharmacoeconomics 9:506–516PubMedCrossRef
12.
go back to reference Desgagne A, Castilloux AM, Angers JF, LeLorier J (1998) The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics 13:487–497PubMedCrossRef Desgagne A, Castilloux AM, Angers JF, LeLorier J (1998) The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics 13:487–497PubMedCrossRef
13.
go back to reference Devlin N, Parkin D (2004) Does NICE have a cost–effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 13:437–452PubMedCrossRef Devlin N, Parkin D (2004) Does NICE have a cost–effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 13:437–452PubMedCrossRef
14.
go back to reference Drummond MF, Jefferson TO (1996) Guidelines for authors and peer reviewers of economic submissions to the BMJ The BMJ Economic Evaluation Working Party. BMJ 313:275–283PubMed Drummond MF, Jefferson TO (1996) Guidelines for authors and peer reviewers of economic submissions to the BMJ The BMJ Economic Evaluation Working Party. BMJ 313:275–283PubMed
15.
go back to reference Drummond MF, O’Brien B, Stoddart GL, Torrance GW (1997) Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, Oxford Drummond MF, O’Brien B, Stoddart GL, Torrance GW (1997) Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, Oxford
16.
go back to reference Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B (2004) Use of cost–effectiveness analysis in health-care resource allocation decision-making: how are cost–effectiveness thresholds expected to emerge? Value Health 7:518–528PubMedCrossRef Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B (2004) Use of cost–effectiveness analysis in health-care resource allocation decision-making: how are cost–effectiveness thresholds expected to emerge? Value Health 7:518–528PubMedCrossRef
17.
go back to reference Evers S, Goossens M, de Vet HC, van Tulder M, Ament A (2005) Assessment of methodological quality of economic evaluations-CHEC. Int J Technol Assess Health Care Evers S, Goossens M, de Vet HC, van Tulder M, Ament A (2005) Assessment of methodological quality of economic evaluations-CHEC. Int J Technol Assess Health Care
18.
go back to reference Fenwick E, O’Brien BJ, Briggs A (2004) Cost–effectiveness acceptability curves—facts, fallacies and frequently asked questions. Health Econ 13:405–415PubMedCrossRef Fenwick E, O’Brien BJ, Briggs A (2004) Cost–effectiveness acceptability curves—facts, fallacies and frequently asked questions. Health Econ 13:405–415PubMedCrossRef
19.
go back to reference Fritzell P, Hagg O, Jonsson D, Nordwall A (2004) Cost–effectiveness of lumbar fusion and nonsurgical treatment for chronic low back pain in the Swedish Lumbar Spine Study: a multicenter, randomized, controlled trial from the Swedish Lumbar Spine Study Group. Spine 29:421–434PubMedCrossRef Fritzell P, Hagg O, Jonsson D, Nordwall A (2004) Cost–effectiveness of lumbar fusion and nonsurgical treatment for chronic low back pain in the Swedish Lumbar Spine Study: a multicenter, randomized, controlled trial from the Swedish Lumbar Spine Study Group. Spine 29:421–434PubMedCrossRef
20.
go back to reference Gafni A, Birch S (1993) Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. CMAJ 148:913–917PubMed Gafni A, Birch S (1993) Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. CMAJ 148:913–917PubMed
21.
go back to reference Gold MR, Siegel JE, Russel LB, Weinstein MC (1996) Cost–effectiveness in health and medicine. Oxford University Press, New York Gold MR, Siegel JE, Russel LB, Weinstein MC (1996) Cost–effectiveness in health and medicine. Oxford University Press, New York
22.
go back to reference Goossens ME, Rutten-van Molken MP, Vlaeyen JW, van der Linden SM (2000) The cost diary: a method to measure direct and indirect costs in cost–effectiveness research. J Clin Epidemiol 53:688–695PubMedCrossRef Goossens ME, Rutten-van Molken MP, Vlaeyen JW, van der Linden SM (2000) The cost diary: a method to measure direct and indirect costs in cost–effectiveness research. J Clin Epidemiol 53:688–695PubMedCrossRef
23.
go back to reference Gravelle H, Smith D (2001) Discounting for health effects in cost–benefit and cost–effectiveness analysis. Health Econ 10:587–599PubMedCrossRef Gravelle H, Smith D (2001) Discounting for health effects in cost–benefit and cost–effectiveness analysis. Health Econ 10:587–599PubMedCrossRef
24.
go back to reference Graves N, Walker D, Raine R, Hutchings A, Roberts JA (2002) Cost data for individual patients included in clinical studies: no amount of statistical analysis can compensate for inadequate costing methods. Health Econ 11:735–739PubMedCrossRef Graves N, Walker D, Raine R, Hutchings A, Roberts JA (2002) Cost data for individual patients included in clinical studies: no amount of statistical analysis can compensate for inadequate costing methods. Health Econ 11:735–739PubMedCrossRef
25.
go back to reference Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG (2000) Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 20:332–342PubMedCrossRef Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG (2000) Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 20:332–342PubMedCrossRef
26.
go back to reference Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L (1995) The friction cost method for measuring indirect costs of disease. J Health Econ 14:171–189PubMedCrossRef Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L (1995) The friction cost method for measuring indirect costs of disease. J Health Econ 14:171–189PubMedCrossRef
27.
go back to reference Korthals-de Bos IB, Hoving JL, Van Tulder MW, Rutten-van Molken MP, Ader HJ, de Vet HC, et al. (2003) Cost effectiveness of physiotherapy, manual therapy, and general practitioner care for neck pain: economic evaluation alongside a randomised controlled trial. BMJ 326:911PubMedCrossRef Korthals-de Bos IB, Hoving JL, Van Tulder MW, Rutten-van Molken MP, Ader HJ, de Vet HC, et al. (2003) Cost effectiveness of physiotherapy, manual therapy, and general practitioner care for neck pain: economic evaluation alongside a randomised controlled trial. BMJ 326:911PubMedCrossRef
28.
go back to reference Kovacs FM, Llobera J, Abraira V, Lazaro P, Pozo F, Kleinbaum D (2002) Effectiveness and cost–effectiveness analysis of neuroreflexotherapy for subacute and chronic low back pain in routine general practice: a cluster randomized, controlled trial. Spine 27:1149–1159PubMedCrossRef Kovacs FM, Llobera J, Abraira V, Lazaro P, Pozo F, Kleinbaum D (2002) Effectiveness and cost–effectiveness analysis of neuroreflexotherapy for subacute and chronic low back pain in routine general practice: a cluster randomized, controlled trial. Spine 27:1149–1159PubMedCrossRef
29.
go back to reference Nixon RM, Thompson SG (2004) Parametric modelling of cost data in medical studies. Stat Med 23:1311–1331PubMedCrossRef Nixon RM, Thompson SG (2004) Parametric modelling of cost data in medical studies. Stat Med 23:1311–1331PubMedCrossRef
30.
go back to reference O’Brien BJ, Briggs AH (2002) Analysis of uncertainty in health care cost–effectiveness studies: an introduction to statistical issues and methods. Stat Methods Med Res 11:455–468PubMedCrossRef O’Brien BJ, Briggs AH (2002) Analysis of uncertainty in health care cost–effectiveness studies: an introduction to statistical issues and methods. Stat Methods Med Res 11:455–468PubMedCrossRef
31.
go back to reference O’Hagan A, Stevens JW (2003) Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality? Health Econ 12:33–49PubMedCrossRef O’Hagan A, Stevens JW (2003) Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality? Health Econ 12:33–49PubMedCrossRef
32.
go back to reference Oostenbrink JB, Al MJ (2005) The analysis of incomplete cost data due to dropout. Health Econ Oostenbrink JB, Al MJ (2005) The analysis of incomplete cost data due to dropout. Health Econ
33.
go back to reference Oostenbrink JB, Koopmanschap MA, Rutten FF (2002) Standardisation of costs: the Dutch Manual for Costing in economic evaluations. Pharmacoeconomics 20:443–454PubMedCrossRef Oostenbrink JB, Koopmanschap MA, Rutten FF (2002) Standardisation of costs: the Dutch Manual for Costing in economic evaluations. Pharmacoeconomics 20:443–454PubMedCrossRef
34.
go back to reference Oostenbrink JB, Al MJ, Rutten-van Molken MP (2003) Methods to analyse cost data of patients who withdraw in a clinical trial setting. Pharmacoeconomics 21:1103–1112PubMedCrossRef Oostenbrink JB, Al MJ, Rutten-van Molken MP (2003) Methods to analyse cost data of patients who withdraw in a clinical trial setting. Pharmacoeconomics 21:1103–1112PubMedCrossRef
35.
go back to reference Palmer S, Byford S, Raftery J (1999) Economics notes: types of economic evaluation. BMJ 318:1349PubMed Palmer S, Byford S, Raftery J (1999) Economics notes: types of economic evaluation. BMJ 318:1349PubMed
36.
go back to reference Polsky D, Glick HA, Willke R, Schulman K (1997) Confidence intervals for cost–effectiveness ratios: a comparison of four methods. Health Econ 6:243–252PubMedCrossRef Polsky D, Glick HA, Willke R, Schulman K (1997) Confidence intervals for cost–effectiveness ratios: a comparison of four methods. Health Econ 6:243–252PubMedCrossRef
38.
go back to reference van der Roer N, Goossens M, Evers S, van Tulder M (2005) What is the most cost-effective treatment for patients with low back pain? A systematic review. Best Pract Res Clin Rheumatol van der Roer N, Goossens M, Evers S, van Tulder M (2005) What is the most cost-effective treatment for patients with low back pain? A systematic review. Best Pract Res Clin Rheumatol
39.
go back to reference Seferlis T, Lindholm L, Nemeth G (2000) Cost-minimisation analysis of three conservative treatment programmes in 180 patients sick-listed for acute low-back pain. Scand J Prim Health Care 18:53–57PubMedCrossRef Seferlis T, Lindholm L, Nemeth G (2000) Cost-minimisation analysis of three conservative treatment programmes in 180 patients sick-listed for acute low-back pain. Scand J Prim Health Care 18:53–57PubMedCrossRef
40.
go back to reference Sendi PP, Briggs AH (2001) Affordability and cost–effectiveness: decision-making on the cost–effectiveness plane. Health Econ 10:675–680PubMedCrossRef Sendi PP, Briggs AH (2001) Affordability and cost–effectiveness: decision-making on the cost–effectiveness plane. Health Econ 10:675–680PubMedCrossRef
41.
go back to reference Siegel JE, Weinstein MC, Russell LB, Gold MR (1996) Recommendations for reporting cost–effectiveness analyses. Panel on cost–effectiveness in health and medicine. JAMA 276:1339–1341PubMedCrossRef Siegel JE, Weinstein MC, Russell LB, Gold MR (1996) Recommendations for reporting cost–effectiveness analyses. Panel on cost–effectiveness in health and medicine. JAMA 276:1339–1341PubMedCrossRef
42.
go back to reference Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR (1997) Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost effectiveness in health and medicine. Pharmacoeconomics 11:159–168PubMedCrossRef Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR (1997) Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost effectiveness in health and medicine. Pharmacoeconomics 11:159–168PubMedCrossRef
43.
go back to reference Stinnett AA, Mullahy J (1998) Net health benefits: a new framework for the analysis of uncertainty in cost–effectiveness analysis. Med Decis Making 18:S68–S80PubMedCrossRef Stinnett AA, Mullahy J (1998) Net health benefits: a new framework for the analysis of uncertainty in cost–effectiveness analysis. Med Decis Making 18:S68–S80PubMedCrossRef
44.
go back to reference Taylor RS, Drummond MF, Salkeld G, Sullivan SD (2004) Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ 329:972–975PubMedCrossRef Taylor RS, Drummond MF, Salkeld G, Sullivan SD (2004) Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ 329:972–975PubMedCrossRef
45.
go back to reference Thompson S (2002) Statistical issues in cost–effectiveness analyses. Stat Methods Med Res 11:453–454PubMedCrossRef Thompson S (2002) Statistical issues in cost–effectiveness analyses. Stat Methods Med Res 11:453–454PubMedCrossRef
46.
go back to reference Thompson SG, Barber JA (2000) How should cost data in pragmatic randomised trials be analysed? BMJ 320:1197–1200PubMedCrossRef Thompson SG, Barber JA (2000) How should cost data in pragmatic randomised trials be analysed? BMJ 320:1197–1200PubMedCrossRef
47.
go back to reference Van Hout BA, Al MJ, Gordon GS, Rutten FF (1994) Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 3:309–319PubMedCrossRef Van Hout BA, Al MJ, Gordon GS, Rutten FF (1994) Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 3:309–319PubMedCrossRef
48.
go back to reference Van Tulder MW, Koes BW, Bouter LM (1995) A cost-of-illness study of back pain in The Netherlands. Pain 62:233–240PubMedCrossRef Van Tulder MW, Koes BW, Bouter LM (1995) A cost-of-illness study of back pain in The Netherlands. Pain 62:233–240PubMedCrossRef
Metadata
Title
Economic evaluations: a new avenue of outcome assessment in spinal disorders
Authors
Nicole van der Roer
Norbert Boos
Maurits W. van Tulder
Publication date
01-01-2006
Publisher
Springer-Verlag
Published in
European Spine Journal / Issue Special Issue 1/2006
Print ISSN: 0940-6719
Electronic ISSN: 1432-0932
DOI
https://doi.org/10.1007/s00586-005-1052-x

Other articles of this Special Issue 1/2006

European Spine Journal 1/2006 Go to the issue